NCT05326347View on ClinicalTrials.gov

A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2025

Conditions
Schizophrenia
Interventions
DRUG

OPC-34712FUM/ Brexpiprazole fumarate

The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.

Trial Locations (1)

Unknown

Hayakawa Clinic, Kure-shi

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY